OvagenОваген
A short-peptide product described as containing glutamate, aspartate and leucine. Published product reports do not establish the order of these residues in the tested formulation.
What the studies found
Comparison in people · 2011
Oral Ovagen in chronic hepatitis and after chemotherapy
- Total bilirubin
- 21.5 vs 26.4 µmol/LOvagen plus usual care versus usual care. Shared baseline column 28.4 µmol/L.Ovagen result marked p < 0.05 versus baseline.
- ALT
- 41.4 vs 44.3Ovagen plus usual care versus usual care. Shared baseline column 50.2. The table has a garbled unit label.Both post-treatment results marked p < 0.05 versus baseline.
- IgM
- 2.1 vs 2.5 g/LOvagen plus usual care versus usual care. Shared baseline column 3.6 g/L.Both post-treatment results marked p < 0.05 versus baseline.
In the chronic-hepatitis table, bilirubin was 28.4 µmol/L before treatment, 21.5 after adjunctive Ovagen and 26.4 after usual care. ALT and IgM were marked lower than baseline in both groups.
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
More reported outcomes
- Cholesterol, AST, GGT and triglycerides
- No significant change markedNo baseline-comparison asterisks on these rows.
- Reported adverse effects
- None reportedObservation was short. The report provides no structured adverse-event table.
Study notes · methods, sources and limitations
Participants or model 40 receiving adjunctive Ovagen (20 with persistent chronic hepatitis, 20 after chemotherapy) and 34 usual-care controls. The treated series was aged 38–67.
Design Adjunct-use comparison of 40 treated and 34 usual-care controls. The outcome tables below concern chronic hepatitis. The reported oral course was 15–20 days in the group description.
Important limitations
- The report provides a shared baseline column and omits comparator subgroup sizes and allocation methods. Significance markers compare values with baseline. The 2011 compilation reproduces a 2005–2006 study and does not authenticate the protocol or establish that this product was the EDL sequence tested in kidney models.
- The shared baseline and unspecified allocation prevent a reliable estimate of an effect attributable to Ovagen.
St. Petersburg Institute of Bioregulation and Gerontology Medical Center report (commercial reproduction) · Institute report — commercial reproduction
About Ovagen
Research background
Ovagen is an oral peptide preparation studied alongside conventional care in chronic hepatitis and after chemotherapy. Experiments with synthetic EDL appear on the EDL profile.
- Compound class
- Peptide product / formulation research
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Institute-report reproduction covering 40 adjunct-treatment patients and 34 usual-care controls.
Study methods
Oral adjunct-treatment comparison, blood markers and liver ultrasound. Allocation unclear.
Independent replication
Independent replication not established in this collection
Source access
See source-specific abstracts, institute reports and explicit review scopes
Safety evidence
Systematic safety assessment incomplete
Open a topic for the evidence assessment.
Findings by study
Comparison in people · 2011
Oral Ovagen in chronic hepatitis and after chemotherapy
In the chronic-hepatitis table, bilirubin was 28.4 µmol/L before treatment, 21.5 after adjunctive Ovagen and 26.4 after usual care. ALT and IgM were marked lower than baseline in both groups.
Study notes and original source
Oral Ovagen in chronic hepatitis and after chemotherapy
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Named oral Ovagen product. The report lists glutamic acid, aspartic acid and leucine, with no sequence or batch characterization. · Institute report — commercial reproduction
A. A. Veretenko, O. Yu. Raigorodskii · St. Petersburg Institute of Bioregulation and Gerontology Medical Center report (commercial reproduction)
In the chronic-hepatitis table, bilirubin was 28.4 µmol/L before treatment, 21.5 after adjunctive Ovagen and 26.4 after usual care. ALT and IgM were marked lower than baseline in both groups.
Results and tables
Reported findings and study design
Adjunct-use comparison of 40 treated and 34 usual-care controls. The outcome tables below concern chronic hepatitis. The reported oral course was 15–20 days in the group description.
Population or model 40 receiving adjunctive Ovagen (20 with persistent chronic hepatitis, 20 after chemotherapy) and 34 usual-care controls. The treated series was aged 38–67.
Dose, route and schedule
The group methods describe two 0.100 mg capsules twice daily before meals for 15–20 days, alongside usual care. The introduction gives a broader tablet schedule of one to two twice daily for 10–20 days.
Protocol source ↗ · Russian commercial reproduction of the 2011 institute report, methods and Tables 1–3
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Total bilirubin | 21.5 vs 26.4 µmol/L | Ovagen plus usual care versus usual care. Shared baseline column 28.4 µmol/L. · Ovagen result marked p < 0.05 versus baseline. |
| ALT | 41.4 vs 44.3 | Ovagen plus usual care versus usual care. Shared baseline column 50.2. The table has a garbled unit label. · Both post-treatment results marked p < 0.05 versus baseline. |
| IgM | 2.1 vs 2.5 g/L | Ovagen plus usual care versus usual care. Shared baseline column 3.6 g/L. · Both post-treatment results marked p < 0.05 versus baseline. |
| Cholesterol, AST, GGT and triglycerides | No significant change marked | No baseline-comparison asterisks on these rows. |
| Reported adverse effects | None reported | Observation was short. The report provides no structured adverse-event table. |
Tables 2–3 · selected chronic-hepatitis measurements
| Measure | Baseline column | Usual care | Usual care + Ovagen |
|---|---|---|---|
| Bilirubin (µmol/L) | 28.4 ± 0.5 | 26.4 ± 1.1 | 21.5 ± 0.7* |
| ALT (unit unclear) | 50.2 ± 3.2 | 44.3 ± 3.1* | 41.4 ± 2.8* |
| AST (unit unclear) | 38.6 ± 2.1 | 40.2 ± 2.2 | 36.1 ± 2.5 |
| IgM (g/L) | 3.6 ± 0.03 | 2.5 ± 0.08* | 2.1 ± 0.03* |
| IgG (g/L) | 14.0 ± 1.2 | 14.2 ± 1.0 | 14.1 ± 1.1 |
Asterisks are from the source and indicate p < 0.05 versus the pretreatment value. The type of ± term is unspecified.
The shared baseline and unspecified allocation prevent a reliable estimate of an effect attributable to Ovagen.
Source for these results ↗ · Reviewed 2026-11-13
- Population / setting
- 40 receiving adjunctive Ovagen (20 with persistent chronic hepatitis, 20 after chemotherapy) and 34 usual-care controls. The treated series was aged 38–67.
- Source reviewed
- Russian commercial reproduction of the 2011 institute report, methods and Tables 1–3
Study limitations
- The report provides a shared baseline column and omits comparator subgroup sizes and allocation methods. Significance markers compare values with baseline.
- The 2011 compilation reproduces a 2005–2006 study and does not authenticate the protocol or establish that this product was the EDL sequence tested in kidney models.
Reviewed 2026-11-13.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗